A Study of RSLV-132 in Females with Primary Sjögren's Syndrome
- Conditions
- Primary Sjögren Syndrome
- Interventions
- Drug: RSLV-132Drug: Placebo
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 106
- Registration Number
- NCT06440525
- Locations
- 🇺🇸
Life Medical Research, Miami Gardens, Florida, United States
🇺🇸Advanced Clinical Research Center, San Diego, California, United States
🇺🇸Evolution Research Center, Hialeah, Florida, United States
Phase 2 Study of RSLV-132 in Subjects With Long COVID
- Conditions
- Post-acute Corona Virus 19 (COVID-19) (Long COVID)
- Interventions
- Drug: RSLV-132Drug: Sodium Chloride 0.9%
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 112
- Registration Number
- NCT04944121
- Locations
- 🇺🇸
Resolve Clinical Center, Seattle, Washington, United States
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
- Conditions
- Sjogren's Syndrome
- Interventions
- Drug: PlaceboDrug: RSLV-132
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT03247686
- Locations
- 🇬🇧
University Hospitals Birmingham, Birmingham, Edgbaston, United Kingdom
🇬🇧Newcastle upon Tyne Hospitals, Newcastle upon Tyne, Gosforth, United Kingdom
A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: PlaceboDrug: RSLV-132
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT02660944
- Locations
- 🇺🇸
Feinstein Institute for Medical Research, Manhasset, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Temple University, Philadelphia, Pennsylvania, United States
Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: RSLV-132
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT02194400
- Locations
- 🇺🇸
West Michigan Rheumatology, Grand Rapids, Michigan, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸Clinical Research of West Florida, Clearwater, Florida, United States